A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification
| Autor: | Sune Boris Nygård, Sönke Detlefsen, Diana R. Andersen, Per Pfeiffer, Camilla Qvortrup, Signe Lykke Nielsen, Line Schmidt Tarpgaard, Nils Brünner, Jan Stenvang, Niels Frank Jensen |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male 0301 basic medicine Oncology Cancer Research medicine.medical_specialty Organoplatinum Compounds Anthracycline Colorectal cancer medicine.medical_treatment Phases of clinical research Disease-Free Survival Study Protocol 03 medical and health sciences 0302 clinical medicine Breast cancer Antigens Neoplasm Internal medicine Gene duplication Genetics medicine Humans Poly-ADP-Ribose Binding Proteins In Situ Hybridization Fluorescence Epirubicin Chemotherapy business.industry Gene Amplification Middle Aged Prognosis medicine.disease Oxaliplatin DNA-Binding Proteins DNA Topoisomerases Type II 030104 developmental biology 030220 oncology & carcinogenesis Female Colorectal Neoplasms business medicine.drug |
| Zdroj: | BMC Cancer Tarpgaard, L S, Qvortrup, C, Nygård, S B, Nielsen, S L, Andersen, D R, Jensen, N F, Stenvang, J, Detlefsen, S, Brünner, N & Pfeiffer, P 2016, ' A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification ', BMC Cancer, vol. 16, 91 . https://doi.org/10.1186/s12885-016-2124-5 Tarpgaard, L S, Qvortrup, C, Nygård, S B, Nielsen, S L, Andersen, D R, Jensen, N F, Stenvang, J, Detlefsen, S, Brünner, N & Pfeiffer, P 2016, ' A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification ', B M C Cancer, vol. 16, 91 . https://doi.org/10.1186/s12885-016-2124-5 |
| ISSN: | 1471-2407 |
| Popis: | UNLABELLED: ᅟ: The overall purpose of this study is to provide proof of concept for introducing the anthracycline epirubicin as an effective, biomarker-guided treatment for metastatic colorectal cancer (mCRC) patients who are refractory to treatment with oxaliplatin-based chemotherapy and have TOP2A gene amplification in their tumor cells.BACKGROUND: Epirubicin is an anthracycline that targets DNA topoisomerase 2-α enzyme encoded by the TOP2A gene. It is used for treatment of several malignancies, but currently not in CRC. TOP2A gene amplifications predict improved efficacy of epirubicin in patients with breast cancer and thus could be an alternative option for patients with CRC and amplified TOP2A gene. We have previously analysed the frequency of TOP2A gene aberrations in CRC and found that 46.6 % of these tumors had TOP2A copy gain and 2.0 % had loss of TOP2A when compared to adjacent normal tissue. The TOP2A gene is located on chromosome 17 and when the TOP2A/CEN-17 ratio was applied to identify tumors with gene loss or amplifications, 10.5 % had a ratio ≥ 1.5 consistent with gene amplification and 2.6 % had a ratio ≤ 0.8 suggesting gene deletions. Based on these observations and the knowledge gained from treatment of breast cancer patients, we have initiated a prospective clinical, phase II protocol using epirubicin (90 mg/m2 iv q 3 weeks) in mCRC patients, who are refractory to treatment with oxaliplatin.METHODS/DESIGN: The study is an open label, single arm, phase II study, investigating the efficacy of epirubicin in patients with oxaliplatin refractory mCRC and with a cancer cell TOP2A/CEN-17 ratio ≥ 1.5. TOP2A gene amplification measured by fluorescence in situ hybridization. A total of 25 evaluable patients (15 + 10 in two steps) will be included (Simon's two-stage minimax design). Every nine weeks, response is measured by computed tomography imaging and evaluated according to RECIST 1.1. The primary end-point of the study is progression-free survival.TRIAL REGISTRATION: Eudract no. 2013-001648-79 . |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|